4.5 Review

Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/rapm-2022-103591

关键词

Opioid-Related Disorders; Analgesics; Opioid; COVID-19; CHRONIC PAIN; Pain Management

向作者/读者索取更多资源

The COVID-19 pandemic has exacerbated the opioid crisis in the USA and Canada. The analysis of service utilization, urine drug testing results, and naloxone dispensation showed significant increases in opioid-related emergency medicine utilization and positive drug test results. These findings highlight the need to enhance prevention, treatment, and harm reduction efforts for the opioid crisis as the pandemic continues.
Importance The COVID-19 pandemic impacted healthcare beyond COVID-19 infections. A better understanding of how COVID-19 worsened the opioid crisis has potential to inform future response efforts. Objective To summarize changes from the COVID-19 pandemic on outcomes regarding opioid use and misuse in the USA and Canada. Evidence review We searched MEDLINE via PubMed, EMBASE, and CENTRAL for peer-reviewed articles published between March 2020 and December 2021 that examined outcomes relevant to patients with opioid use, misuse, and opioid use disorder by comparing the period before vs after COVID-19 onset in the USA and Canada. Two reviewers independently screened studies, extracted data, assessed methodological quality and bias via Newcastle-Ottawa Scale, and synthesized results. Findings Among 20 included studies, 13 (65%) analyzed service utilization, 6 (30%) analyzed urine drug testing results, and 2 (10%) analyzed naloxone dispensation. Opioid-related emergency medicine utilization increased in most studies (85%, 11/13) for both service calls (17% to 61%) and emergency department visits (42% to 122%). Urine drug testing positivity results increased in all studies (100%, 6/6) for fentanyl (34% to 138%), most (80%, 4/5) studies for heroin (-12% to 62%), and most (75%, 3/4) studies for oxycodone (0% to 44%). Naloxone dispensation was unchanged and decreased in one study each. Interpretation Significant increases in surrogate measures of the opioid crisis coincided with the onset of COVID-19. These findings serve as a call to action to redouble prevention, treatment, and harm reduction efforts for the opioid crisis as the pandemic evolves. PROSPERO registration number CRD42021236464.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据